2016
Authors: European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord.
Published in: Antivir Ther. 2016; 21(4): 353-8
Background Surveillance for mid- and long-term antiretroviral therapy (ART) toxicity in children is important for informing treatment guidelines. We assessed the safety of darunavir (DRV) and atazanavir (ATV), commonly used as second-line protease inhibitors following lopinavir/ritonavir,
2016
Authors: Judd A, Sohn A, Collins J.
Published in: Curr Opin HIV AIDS 2016;11(5):477-486.
Purpose of review There is an increasing number of deaths among adult survivors of perinatal HIV. Multiple and complex factors drive this mortality, including problems with retention in care and adherence during adolescence,
2016
Authors: Ngo-Giang-Huong N, Wittkop L, Judd A, et al. For EuroCoord-CHAIN-EPPICC joint project study group.
Published in: BMC Infect Dis. 2016;16(1):654.
Background Few studies have evaluated the impact of pre-treatment drug resistance (PDR) on response to combination antiretroviral treatment (cART) in children. The objective of this joint EuroCoord-CHAIN-EPPICC/PENTA project was to assess the prevalence of PDR mutations and their association with virological outcome in the first year of cART in children.
2016
2016
Authors: Schalkwijk S, ter Heine R, Colbers A, Huitema A, Denti P, Dooley K, Capparelli E, Best B, Cressey T, Greupink R, Russel F, Mirochnick M, Burger D.
Published: 17th edition of the International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, June 8th-10th 2016, Washington DC. P_26
2016
Authors: Colbers A, Schalkwijk S, Konopnicki D, Hawkins D, Hidalgo Tenorio C, Moltò J, Taylor G, Weizsacker K, van der Ende M, Burger D
Published: Oral presentation at 17th edition of the International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, June 8th-10th 2016, Washington DC
2016
Authors: Schalkwijk S, Best B, Colbers A, SteK A, Wang J, Hawkins D, Mirochnick M, Burger D; for the The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1026s Protocol Team, and the Pharmacokinetics of Newly Developed Antiretroviral Agents in HIV-infected Pregnant Women (PANNA) Study Network
Published: 23rd Conference on Retroviruses and Opportunistic Infections, February 22nd-25th 2016, Boston
2016
Authors: Blonk MI, Colbers AP, HidalgoTenorio C, et al.
Published in: Front Pharmacol. 2016 Aug 4;7:239.
Background: The study goal was to describe etravirine pharmacokinetics during pregnancy and postpartum in HIV-infected women.
Methods: IMPAACT P1026s and PANNA are on-going, non-randomized, open-label, parallel-group, multi-center phase-IV prospective studies in HIV-infected pregnant women.
2016
Authors: Schalkwijk S, Feiterna-Sperling C, Weizsacker K, et al.
Published in: AIDS. 2016; 30(12):1999-2001.
No Abstract available
2016
Author: Butler K, Inshaw J, Ford D, et al.
Published in: Health Technol Assess. 2016;20(49):1-108.
Background For human immunodeficiency virus (HIV)-infected adolescents facing lifelong antiretroviral therapy (ART), short-cycle therapy (SCT) with long-acting agents offers the potential for drug-free weekends, less toxicity, better adherence and cost savings.
Objectives To determine whether or not efavirenz (EFV)-based ART in short cycles of 5 days on and 2 days off is as efficacious (in maintaining virological suppression) as continuous EFV-based ART (continuous therapy;
2016
Author: The BREATHER (PENTA 16) Trial Group
Published in: Lancet HIV. 2016;3(9):e421-430
Background For HIV-1-infected young people facing lifelong antiretroviral therapy (ART), short cycle therapy with long-acting drugs offers potential for drug-free weekends, less toxicity, and better quality-of-life. We aimed to compare short cycle therapy (5 days on, 2 days off ART) versus continuous therapy (continuous ART).
2016
Authors: Schalkwijk S, Colbers A, Konopnicki D, et al. For PANNA network
Published in: AIDS. 2016;30(8):1239-44.
Objective To describe the pharmacokinetics of abacavir 600 mg once daily (q.d.) in HIV-1-positive women during pregnancy and postpartum.
Design A nonrandomized, open-label, multicentre, phase-IV study.
Methods HIV-positive pregnant women receiving abacavir 600 mg q.d.
2016
Authors: Aebi-Popp K, Bailey H, Malyuta R, Volokha A, Thorne C. Ukraine European Collaborative Study in EuroCoord.
Published in: BMC Pregnancy Childbirth. 2016;27;16:94
Background Over 3500 HIV-positive women give birth annually in Ukraine, a setting with high prevalence of sexually transmitted infections. Herpes simplex virus Type 2 (HSV-2) co-infection may increase HIV mother-to-child transmission (MTCT) risk.
2016
Authors: Ananworanich J, Melvin D, Ramos Amador JT, et al; on behalf of the PENTA 11 study group.
Published in: AIDS. 2016;30(7):1075-81.
Objective Understanding the effects of antiretroviral treatment (ART) interruption on neurocognition and quality of life (QoL) are important for managing unplanned interruptions and planned interruptions in HIV cure research.
Design Children previously randomized to continuous (continuous ART,
2016
Authors: Schalkwijk S, Colbers A, Konopnicki D, Greupink R, Russel FG, Burger D; PANNA network.
Published in: AIDS. 2016;30(5):807-8.
Abstract not available
2016
Authors: Writing group for the Kids to Adults Working Group and Data Management and Harmonisation Group in EuroCoord.
Published in: Euro Surveill.2016;21(10): 30162
Abstract Accurate ascertainment of the number of children living with human immunodeficiency virus (HIV) is important to plan paediatric and adolescent health services. In Europe, the first generation of perinatally HIV-infected survivors are transferring to adult care and their health needs are unknown.
2016
Author: Warris A; European Paediatric Mycology Network (EPMyN)*.
Published in: Curr Fungal Infect Rep. 2016;10:7-9.
Abstract: The European Paediatric Mycology Network (EPMyN) was launched in 2014 to create a European platform for research and education in the field of paediatric mycology. The EPMyN aims to address the lack of paediatric specific evidence and knowledge needed to (1) improve the management and outcome of invasive fungal infections in children and neonates and to (2) enhance and develop paediatric anti-fungal stewardship programmes.
2016
Authors: S. Bernays, S. Paparini, D. Gibb & J. Seeley
Published in: Vulnerable Child Youth Stud. 2016;11(1):60-68
Abstract Despite mounting evidence recommending disclosure of human immunodeficiency virus (HIV) status to young people with perinatally acquired HIV as a central motivating factor for adherence to antiretroviral therapy, many young people continue to experience disclosure as a partial event,
2015
Authors: Moltò J, Valle M, Colbers A, Clotet V, Burger D.
Published: 16th edition of the International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, May 26th – 28th 2015, Westin Alexandria
2015
Authors: Harrison L, Melvin A, Fiscus S, et al. For PENPACT-1 (PENTA 9PACTG 390) Study Team.
Published in: JAIDS 2015;70(1):42-53
Background The PENPACT-1 trial compared virologic thresholds to determine when to switch to second-line antiretroviral therapy (ART). Using PENPACT-1 data, we aimed to describe HIV-1 drug resistance accumulation on first-line ART by virologic threshold.
Methods PENPACT-1 had a 2 × 2 factorial design,
2015
Authors: Bernays S, Seeley J, Paparini S, Rhodes T
Published: BSA Medical Sociology Conference, York, 9-11 September 2015 (Paper ID No: W0012148)
2015
Authors: Blonk MI, Colbers AP, Hidalgo-Tenorio C, et al. Pharmacokinetics of Newly Developed Antiretroviral Agents in HIV-Infected Pregnant Women PANNA Network; PANNA Network.
Published in: Clin Infect Dis. 2015; 61(5):809-816.
BackgroundThe use of raltegravir in human immunodeficiency virus (HIV)–infected pregnant women is important in the prevention of mother-to-child HIV transmission,
2015
Authors: Colbers A, Clotet V, Burger D.
Published: 16th edition of the International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, May 26th – 28th 2015, Westin Alexandria
2015
Authors: Best B, Colbers A, Wang J, Taylor G, Stek A, van Kasteren M, Mirochnick M, Burger D.
Published: 24th Conference on Retroviruses and Opportunistic Infections, March 23rd-26th 2015, Seattle. P_892
2015
Authors: Colbers A, Best B, Schalkwijk S, et al. PANNA Network and the IMPAACT 1026 Study Team.
Published in: Clin Infect Dis. 2015; 61(10):1582-1589.
Objective To describe the pharmacokinetics of maraviroc in human immunodeficiency virus (HIV)–infected women during pregnancy and post partum.
Methods HIV-infected pregnant women receiving maraviroc as part of clinical care had intensive steady-state 12-hour pharmacokinetic profiles performed during the third trimester and ≥2 weeks after delivery.
2015
Authors: Bernays S, Seeley J, Paparini S, Rhodes T and the ARROW and BREATHER trial teams.
Published in: accepted for presentation at AIDS Impact, Amsterdam 28-31 July, 2015 (abstract 3435)
2015
Authors: Paparini S on behalf of Bernays S, Seeley S, Rhodes T, Namukwaya Kihika S,Kawuma-Kigawa R, Nakyambadde H, Kabajaasi O and the BREATHER Trial Team.
Published in: 3rd International ASSHH Conference, Stellenbosch, South Africa, 6-9 July 2015.
2015
Authors: Seeley J on behalf of the Bernays S, Paparini S, Namukwaya Kihika S, Rhodes T and the BREATHER Trial Team.
Published in: 3rd International ASSHH Conference, Stellenbosch, South Africa, 6-9 July 2015.
2015
Authors: Klein N, Palma P, Luzuriaga K, et al.
Published in: Lancet Infect Dis. 2015;15(9):1108-1114
Abstract From the use of antiretroviral therapy to prevent mother-to-child transmission to the possibility of HIV cure hinted at by the Mississippi baby experience, paediatric HIV infection has been pivotal to our understanding of HIV pathogenesis and management. Daily medication and indefinite antiretroviral therapy is recommended for children infected with HIV.
2015
Authors: Seeley J on behalf of the Bernays S, Paparini S, Namukwaya Kihika S, Rhodes T and the BREATHER Trial Team.
Published in: 3rd International ASSHH Conference, Stellenbosch, South Africa, 6-9 July 2015.
2015
Author: Paparini S on behalf of Bernays S, Seeley S, Rhodes T, Namukwaya Kihika S,Kawuma-Kigawa R, Nakyambadde H, Kabajaasi O and the BREATHER Trial Team.
Published in: 3rd International ASSHH Conference, Stellenbosch, South Africa, 6-9 July 2015.
2015
Authors: Bernays S, Seeley J, Paparini S, Rhodes T and the ARROW and BREATHER trial teams
Published in: AIDS Impact, Amsterdam 28-31 July, 2015 (abstract 3435)
2015
Authors: Palma P, Foster C, Rojo P, et al.
Published in: J Virus Erad. 2015;1(3):134-139.
Abstract The EPIICAL (Early-treated Perinatally HIV-infected Individuals: Improving Children’s Actual Life with Novel Immunotherapeutic Strategies) project arises from the firm belief that perinatally infected children treated with suppressive antiretroviral therapy (ART) from early infancy represent the optimal population model in which to study novel immunotherapeutic strategies aimed at achieving ART-free remission.
2015
Authors: Antinori A., Marcotullio S., Andreoni M., Ammassari A., d’Arminio Monforte A., Galli M., Girardi E., Mazzotta F., Mussini C., Puoti M., Lazzarin A.; Italian HIV Guidelines Working Group.
Published in: New Microbiol. 2015, 38: 299-328
Abstract: This short version complies with the intention expressed in the introduction to the full text Italian Guidelines for the use of antiretroviral drugs and the diagnostic-clinical management of people with HIV-1 infection.
2015
Authors: De Bie S., Ferrajolo C., Straus S.M., Verhamme K.M., Bonhoeffer J., Wong I.C., Sturkenboom M.C., GRiP network
Published in: PLoS One. 2015, 10: 0130399.
Abstract: Individual case safety reports (ICSRs) are a cornerstone in drug safety surveillance. The knowledge on using these data specifically for children is limited. We studied characteristics of pediatric ICSRs reported to the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).
2015
Authors: Thorne C, Indolfi G, Turkova A, Giaquinto C, Nastouli E.
Published in: J Virus Erad. 2015 Jul 1;1(3):203-5.
Abstract Hepatitis C virus infection is a leading cause of liver-related morbidity and mortality. In the paediatric population, HCV infection is underdiagnosed and undertreated in the absence of robust screening policies worldwide, and a lack of tolerable,
2015
Authors: Turkova A, Giacomet V, Goetghebuer T, et al.
Published in: J Virus Erad. 2015;1(3):179-184
Objectives To describe use of treatment for chronic hepatitis C virus (HCV) infection in HIV/HCV co-infected children and young people living in Europe and to evaluate treatment outcomes.
Methods HCV treatment data on children and young people aged <25 years with HIV/HCV co-infection were collected in a cohort collaboration of 11 European paediatric HIV cohorts.
2015
Authors: Paediatric European Network for Treatment of AIDS (PENTA).
Published in: AIDS 2015. 29(18):2447-2457
Objective To evaluate whether once daily (q.d.) lopinavir/ritonavir is noninferior to twice daily (b.i.d.) dosing in children.
Design International, multicentre, phase II/III, randomized, open-label, noninferiority trial (KONCERT/PENTA18/ANRS150).
Setting Clinical centres participating in the PENTA,
2015
Authors:
Published in: AIDS 2015, 29:2447-2457
Objective To evaluate whether once daily (q.d.) lopinavir/ritonavir is noninferior to twice daily (b.i.d.) dosing in children.
Design International, multicentre, phase II/III, randomized, open-label, noninferiority trial (KONCERT/PENTA18/ANRS150).
Setting Clinical centres participating in the PENTA, HIV-NAT and PHPT networks.
Participants Children/adolescents with HIV-1 RNA viral load less than 50 copies/ml for at least 24 weeks on lopinavir/ritonavir-containing antiretroviral therapy.
2015
Authors: Karina M. Butler on behalf of the BREATHER trial team
Published in: CROI 2015, Seattle, USA, Feb 23 -26 2015.
Abstract For HIV-1 infected young people (YP) facing lifelong ART, short cycle therapy (SCT) with long-acting agents offers the potential for drug-free weekends, less toxicity and better adherence, as well as cost savings.
2015
Authors: Freguja R, De Rossi A, Paulson H, Klein N, Del Bianco P, Compagnucci A, Saidi Y, Giaquinto C, Harper L, Gibb D, on behalf of the PENTA Steering Committee
Published in: CROI 2015, Seattle, USA, Feb 23 -26 2015. Poster presentation abstract 919
2015
Authors: Colbers A, Molto J, Ivanovic J, et al. PANNA Network
Published in: J Antimicrob Chemother. 2015; 70(2):534-542
Objectives To describe the pharmacokinetics of darunavir in pregnant HIV-infected women in the third trimester and post-partum.
Patients and Methods This was a non-randomized, open-label, multicentre, Phase IV study in HIV-infected pregnant women recruited from HIV treatment centres in Europe.
2015
Authors: Harrison L, Melvin A, Fiscus S, et al; PENPACT-1 (PENTA 9PACTG 390) Study Team.
Published in: J Acquir Immune Defic Syndr. 2015;70(1):42-53
Background The PENPACT-1 trial compared virologic thresholds to determine when to switch to second-line antiretroviral therapy (ART). Using PENPACT-1 data, we aimed to describe HIV-1 drug resistance accumulation on first-line ART by virologic threshold.
2015
Authors: Colbers A, Hawkins D, HidalgoTenorio C, et al.
Published in: Antivir Ther. 2015; 20(1):57-64
Background We studied the effect of pregnancy on atazanavir pharmacokinetics in the presence and absence of tenofovir.
Methods This was a non-randomized, open-label, multicentre Phase IV study in HIV-infected pregnant women recruited from European HIV treatment centres.
2014
Authors: Colbers A, Gingelmaier A, van der Ende M, Rijnders, B, Burger D.
Published in: AIDS 2014;28(2): 288-290
2014
Authors: Bailey H, Townsend C, Semenenko I, Malyuta R, Cortina-Borja, Thorne C; for the Ukraine European Collaborative Study in EuroCoord
Published in: BMC Public Health. 2014; 24(14):993
Background Poor adherence to antiretroviral therapy (ART) is associated with HIV disease progression and, during
pregnancy, increased mother-to-child transmission risk. In Ukraine, access to combination ART is expanding but data
on adherence are scarce.
2014
Authors: Colbers A, Hawkins D, Hidalgo-Tenorio C, van der Ende M, Kabeya K, Gingelmaier A, Weizsäcker K, Lambert J, Rockstroh J, Burger D; on behalf of the PANNA network
Published: 23rd Conference on Retroviruses and Opportunistic Infections, March 3rd-6th 2014, Boston. P_892
2014
Authors: Blonk M, Colbers A, Hidalgo-Tenorio C, Weizsäcker K, Moltó J, Hawkins D, van der Ende M, Gingelmaier A, Taylor G, Burger D; on behalf of the PANNA network
Published: 23rd Conference on Retroviruses and Opportunistic Infections, March 3rd-6th 2014, Boston. P_890
2014
Authors: Colbers A, Moltó J, Ivanovic J, Hawkins D, Sadiq T, Kabeya K, Gingelmaier A, Weizsäcker K, Taylor G, Burger D; on behalf of the PANNA network
Published: 23rd Conference on Retroviruses and Opportunistic Infections, March 3rd-6th 2014, Boston. P_887
2014
Authors: Turkova A; for the European Paediatric HIV/HCV Co-infection Study Group in the European Pregnancy and Paediatric HIV Cohort Collaboration in EuroCoord.
Published in: 20th International AIDS Conference (AIDS 2014), July 20th-25th 2014, Melbourne, Australia.